Anna Sabine

Anna Sabine

Liberal Democrat — Frome and East Somerset

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

It is a pleasure to serve under your chairmanship, Sir John. I thank the right hon. Member for Tatton (Esther McVey) for bringing forward this debate; I know she feels very strongly about this issue, as do many of the rest of us here. One of the first emails I received when I became an MP was from a constituent whose stepson is a victim of the Primodos scandal. Primodos was a hormonal pregnancy test and the scandal around its use is often called the forgotten thalidomide. Taking it in early pregnancy caused limb defects, congenital heart defects, developmental and learning problems, as well as stillbirths and miscarriages. My constituent, and others like her whom I have met since, have told me about the decades of fighting by families and amazing campaigners such as Marie Lyon to receive the justice they deserve for a scandal that has impacted so many lives. Unfortunately, their story is not unique. Primodos, vaginal mesh and the faulty drugs and devices examined by the Cumberlege review: in each case, patients—women—raised concerns and the system, including the MHRA, has not listened. This should be evidence enough that the MHRA needs substantial reform, yet, as we have heard this morning we are still waiting to see many vital changes. At the moment, patients are being failed by the MHRA in two ways: failed when the regulator is too slow to deliver promising treatments, and failed when it is too slow to listen when something goes wrong. The Liberal Democrats want a regulator that does both things well. This is why we are calling for reform to make it both effective and trusted. On the question of speed, there has recently been a welcome turnaround in the MHRA. After years of neglect under the previous Government, nearly all national medicine licence applications in 2025-26 were decided within the statutory 210-day limit. Credit is due here, but that statutory timeline remains too slow. In the UK, it takes an average of 322 days—nearly a year—for a new medicine or medical technology to reach patients, compared with 158 days in Germany. For someone with a rare disease or an aggressive cancer, a promising treatment stuck in a queue uses up time they may not have. Clinical trial targets are also being missed. What is the Government’s plan to improve that? The Liberal Democrats are clear that we would invest in MHRA capacity with the aim of halving the time it takes for new treatments for illnesses such as cancer to reach patients. We would make timeframes more predictable and offer more informal scientific advice from the outset, so that companies can get their products to patients sooner. On the second question, trust, the Liberal Democrats would fully implement the Cumberlege recommendations, including providing compensation for those failed by faulty drugs and devices. That should include Primodos. Finally, I turn to the subject of children with severe drug-resistant epilepsy, such as my constituent Clover, whose case I have raised in this place many times. Families like hers have been fighting for years for medicines that work. Right now, only one cannabis-based medicine is licenced for epilepsy in this country and only for three specific syndromes. Many children whose seizures have finally been brought under control depend on whole-plant medicines that remain unlicensed, so their parents are forced to pay thousands of pounds privately to keep their children alive. Organisations such as the Medcan Family Foundation have been clear about the way forward. The medicines need to be licensed more widely, and the trials that would build that evidence should sit with the MHRA. Ministers say that a licence cannot come without the evidence, but the evidence cannot come without trials that are properly designed, adaptive and up and running. Families have been caught in that loop for far too long. I should say that the Minister’s predecessor met Clover’s family and was incredibly helpful, but he was the eighth Minister they have met in the time they have been campaigning and they feel that they are being passed from pillar to post. The danger is now sharper than ever. Since Bedrocan went bankrupt last month, parents have been left wondering whether the medicine keeping their child alive will even be there in six months’ time. Will the MHRA take ownership of this situation, set out a clear route to licensing and ensure that no child is put at risk because the regulatory system has not kept pace? More generally, will the Government commit to improving MHRA’s capacity, so that it can approve licences quickly, support clinical trials and, more importantly, serve the patients that benefit most from medical innovation? My constituents and thousands of people across the country have waited decades for the MHRA to listen and improve. I hope the Minister will agree to deliver for all the victims of medical scandals.

More from Anna Sabine

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Anna Sabine's full parliamentary record including voting history, expenses and all other contributions, see the Anna Sabine report card.